Skip to main content

MCMDC2 Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-84155

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-84155-0.1ml

Key Product Details

Species Reactivity

Human

Applications

Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit

Concentration

0.5 mg/ml

Product Specifications

Immunogen

The immunogen is a synthetic peptide directed towards the middle region of human MCMDC2. Peptide sequence: RSITVYIPGKKFGEDIDQQMTFPVQCSFWSFVDVDSSSRRNAQKINTLIG The peptide sequence for this immunogen was taken from within the described region.

Clonality

Polyclonal

Host

Rabbit

Scientific Data Images for MCMDC2 Antibody

Western Blot: MCMDC2 Antibody [NBP2-84155]

Western Blot: MCMDC2 Antibody [NBP2-84155]

Western Blot: MCMDC2 Antibody [NBP2-84155] - WB Suggested Anti-C8orf45 Antibody Titration: 0.2-1 ug/ml. Positive Control: Jurkat cell lysate

Applications for MCMDC2 Antibody

Application
Recommended Usage

Western Blot

1.0 ug/ml

Formulation, Preparation, and Storage

Purification

Affinity purified

Formulation

PBS, 2% Sucrose

Preservative

0.09% Sodium Azide

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: MCMDC2

Alternate Names

C8orf45, chromosome 8 open reading frame 45, FLJ25692, minichromosome maintenance complex component-like, minichromosome maintenance domain containing 2

Gene Symbol

MCMDC2

Additional MCMDC2 Products

Product Documents for MCMDC2 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for MCMDC2 Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...